Stuttgart - Delayed Quote EUR

Kyowa Kirin Co Ltd (KY4.SG)

13.00

-0.40

(-2.99%)

At close: May 14 at 8:12:16 AM GMT+2

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that an abstract highlighting clinical data from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational me

GlobeNewswire 11 hours ago

KYKOF

KYKOY

KURA
Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

– Submission seeks approval for the treatment of adult patients with relapsed or refractory AML with a NPM1 mutation –SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”), today announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) acute myelo

GlobeNewswire last month

KYKOF

KYKOY

KURA
35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN

A 35-year academic-industry partnership that has produced groundbreaking discoveries in immunology and supported first-in-class therapies for rare disease patients has entered its 36th year with the signing of a three-year research funding agreement between La Jolla Institute for Immunology (LJI), an independent nonprofit research organization in California, and Kyowa Kirin, Inc., the wholly-owned North American subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a Japan-based global s

PR Newswire last month

KYKOF

KYKOY
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational T-cell rebalancing therapy targeting the OX40 receptor, in moderate to severe atopic dermatitis (AD).

PR Newswire 2 months ago

KYKOF

KYKOY

AMGN
Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025

Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor (OX40R) in patients with moderate-to-severe atopic dermatitis (AD), will be presented at the American Academy of Dermatology (AAD) 2025 Annual Meeting to be held in Orlando, Florida from March 7-11, 2025.

PR Newswire 2 months ago

KYKOF

KYKOY
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

– KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track for 2Q 2025 – – Registrational KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated approval and full approval – – Registrational KOMET-017-NIC trial of venetoclax / azacitidine combination will as

GlobeNewswire 3 months ago

KURA

KYKOF

KYKOY
Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively – – Promising clinical activity in R/R NPM1-m and KMT2A-r AML with ven/aza, including ven-experienced patients – – Ziftomenib generally well tolerated in combination with standards of care at all dose levels studied – – Kura

GlobeNewswire 5 months ago

KURA

KYKOF

KYKOY
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kura Oncology, Inc. (Nasdaq: KURA) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced they have entered into a global strategic collaboration to develop and commercialize ziftomenib, Kura's selective oral menin inhibitor, being investigated for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies.

PR Newswire 5 months ago

KYKOF

KYKOY

KURA
Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

TOKYO, October 31, 2024--Japan-based Global Specialty Pharmaceutical Company Kyowa Kirin Co., Ltd. (President and CEO: Masashi Miyamoto.) (TOKYO:4151) today announced that Masashi Miyamoto, Ph.D. will take the role of Chairman and CEO, after serving as President for the past 7 years. Abdul Mullick, Ph.D., the current Chief International Business Officer (CIBO), will become President and Chief Operating Officer. The changes will come into effect following approval at the Ordinary General Meeting

Business Wire 6 months ago

KYKOF

KYKOY
Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis

Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE:4151) (President and CEO: Masashi Miyamoto) announced top-line results of the Phase 3 ROCKET HORIZON trial of rocatinlimab, an investigational therapy targeting the OX40 receptor. HORIZON met its co-primary endpoints: achievement of a validated Investigator Global Assessment for Atopic Dermatitis (vIGA-ADTM) score of 0 (clear) or 1 (almost clear) with a ≥ 2-point reduction from baseline [19.3% rocatinlimab vs. 6.6% placebo (12.8% difference, p<0.001)] and

PR Newswire 7 months ago

KYKOF

KYKOY
Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting

Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) will share new research that enhances understanding about the use of burosumab in real-world clinical practice as well as the burden of those living with X-linked hypophosphatemia (XLH), a rare genetic metabolic bone disease. The findings will be presented at the American Society for Bone and Mineral Research (ASBMR) 2024 annual meeting, which takes place September 27-30 in Toronto.

PR Newswire 7 months ago

KYKOF

KYKOY
New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), today announced the publication of a new analysis showing low levels of full-time employment and impaired work productivity among working age adults enrolled in the XLH Disease Monitoring Program, a prospective, 10-year, observational study of adults and children with X-linked hypophosphatemia in the US, Canada, and Latin America.

PR Newswire 7 months ago

KYKOF

KYKOY
Kyowa Kirin to end distribution of Fareston (toremefine) in the United States

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, is announcing that it will no longer distribute or fulfill orders for Fareston (toremefine) 60 mg tablets in the United States, effective August 31, 2024. This decision aligns with the company's Vision for 2030 and its focus on the discovery, development and delivery of novel therapies for patients. Kyowa Kirin has previously taken steps to notify the Food

PR Newswire 8 months ago

KYKOF

KYKOY
Kyowa Kirin Announces a New Sustainable Business Strategy for the Asia-Pacific (APAC) Region

Kyowa Kirin Asia Pacific Pte. Ltd., a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto), announced plans to transform its Asia-Pacific (APAC) business for more sustainable and profitable operations, through strategic partnerships with DKSH Holding Ltd. ("DKSH") and Hong Kong Winhealth Pharma Group ("Winhealth").

PR Newswire 9 months ago

KYKOF

KYKOY
Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin) (TSE: 4151), a global specialty pharmaceutical company based in Japan, today announced that its board of directors has approved plans to invest up to $530 million to build a new, state-of-the-art manufacturing facility in Sanford, North Carolina. The 171,700-square-foot, two-reactor facility will accelerate the company's development and production of biologic therapies for patients with rare and serious diseases while also co

PR Newswire 10 months ago

KYKOF

KYKOY

Performance Overview

Return	KY4.SG	Nikkei 225 (^N225)
YTD	-9.09%	-5.42%
1-Year	-0.12%	-1.70%
3-Year	+4,489.69%	+42.78%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kyowa Kirin Co Ltd (KY4.SG)

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

35-YEAR INDUSTRY-ACADEMIC PARTNERSHIP YIELDING GROUNDBREAKING ADVANCES FOR SCIENCE AND PATIENTS RENEWS FOR ANOTHER THREE YEARS BETWEEN LA JOLLA INSTITUTE FOR IMMUNOLOGY AND KYOWA KIRIN

AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Kyowa Kirin Announces Late-Breaking Abstract Presentation at the American Academy of Dermatology Annual Meeting 2025

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Kyowa Kirin Announces Top-line Data from Rocatinlimab Phase 3 ROCKET HORIZON Trial for Adults with Moderate to Severe Atopic Dermatitis

Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting

New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphatemia (XLH)

Kyowa Kirin to end distribution of Fareston (toremefine) in the United States

Kyowa Kirin Announces a New Sustainable Business Strategy for the Asia-Pacific (APAC) Region

Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC

Performance Overview